Citi: Alibaba Stock Could Surge 50% After Blockbuster 6.18 Festival
Citi analyst Alicia Yap reaffirmed her "Buy" rating on the stock with a price target of $169, projecting nearly 50% upside from current levels. She said the latest festival results, combined with upbeat retail trends in April and May, could push Q1 FY26 revenue growth beyond current estimates.
Warning! GuruFocus has detected 3 Warning Signs with BABA.
Tmall President Liu Bo said GMV rose 10% year-over-year, highlighting robust merchant sales. He credited China's trade-in subsidy policy and immediate 10% price discounts as key drivers, which helped improve conversion and reduce returns. The 6.18 event spanned late May to mid-June.
Yap noted early traction from Alibaba's Taobao Quick Commerce and emphasized that AliExpress showed strong global engagement, with livestreams attracting hundreds of thousands of users and some products selling out in markets like the UK and Australia.
The company is now positioning for its next major event, Singles' Day on Nov. 11, by doubling down on high-quality growth strategies.
This report reflects optimism around Alibaba's rebound as it sharpens its domestic and international e-commerce focus.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Amazon (AMZN) Expands Same-Day Grocery Delivery, Escalating Retail Delivery Battle
Inc. (NASDAQ:AMZN) is one of the best growth stocks to buy according to analysts. Inc. (NASDAQ:AMZN) announced on August 13 that it will be expanding its same-day delivery service to include fresh and frozen grocery items for its Prime members. The company did not reveal the cities included in the rollout. Ken Wolter / Starting this week, Prime subscribers in select cities will be able to receive items such as strawberries, milk, meats, and frozen dinners within hours of placing an order. This will intensify competition for same-day deliveries for perishable items, with other retail giants like Walmart. What is likely to work in the e-commerce giant's favor is its improving logistics and Whole Foods' infrastructure. Same-day grocery delivery is a massive battleground in e-commerce, with customers spoiled for choice and expecting faster delivery. The tech behemoth has already been offering grocery delivery through its Amazon Fresh and Whole Foods platforms. However, the latest move indicates a deeper commitment by the company to improve its share in the perishable item segment. If the company can capture a share of the same-day delivery for perishable items and scale up, its impact in the grocery sector is likely to grow; it is likely to put pressure on the traditional grocers and delivery rivals, given Amazon's scale and delivery moat. While we acknowledge the potential of AMZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Times
30 minutes ago
- New York Times
China's Biotech Is Cheaper and Faster
Just outside of Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and laboratories where global pharmaceutical companies can develop and manufacture drugs faster and cheaper than anywhere else. Amid the Trump administration's tariffs on China, I figured manufacturing hubs like this one would be wracked with anxiety. But when I visited Wuxi in April, government officials insisted that its research hub was flourishing. They were proud to tell me about their superstar labs and companies that are continuing to thrive. The fact that Chinese biotechnology stocks have surged over 60 percent since January seems to bolster this claim. The city's researchers certainly seemed positioned to be busy for decades. In its quest to dethrone American dominance in biotech, China isn't necessarily trying to beat America at its own game. While the U.S. biotech industry is known for incubating cutting-edge treatments and cures, China's approach to innovation is mostly focused on speeding up manufacturing and slashing costs. The idea isn't to advance, say, breakthroughs in the gene-editing technology CRISPR; it's to make the country's research, development, testing and production of drugs and medical products hyperefficient and cheaper. As a result, China's biotech sector can deliver drugs and other medical products to customers at much cheaper prices, including inexpensive generics. These may not be world-changing cures, but they are treatments that millions of people around the world rely on every day. And as China's reach expands, the world will soon have to reckon with a new leader in biotech and decide how it wants to respond. One such company that embodies the Chinese approach to biotech is Wuxi AppTec. It's a one-stop shop for pharmaceutical research and development, streamlining everything from early-stage drug discovery to young scientist recruitment and medication production. The company, whose clients have included Chinese firms like Innovent and Jiangsu Hengrui, as well as American and European drugmakers like Pfizer, GlaxoSmithKline and AstraZeneca, was involved in, by one estimate, a quarter of the drugs used in the United States, including blockbuster cancer drugs. Though the Chinese government bargains hard with both foreign and domestic pharmaceutical companies to provide products at the right price in exchange for market access, the low prices that Chinese consumers pay are ultimately the result of Chinese biotech companies' ability to test and manufacture drugs at a pace far faster than their American counterparts. So far, American biotech giants don't seem to mind the competition, since their own use of companies like Wuxi AppTec allows them to dedicate more of their money to breakthrough research. Want all of The Times? Subscribe.
Yahoo
2 hours ago
- Yahoo
Mr D.I.Y. Group (M) Berhad Second Quarter 2025 Earnings: Misses Expectations
Explore Mr D.I.Y. Group (M) Berhad's Fair Values from the Community and select yours Mr D.I.Y. Group (M) Berhad (KLSE:MRDIY) Second Quarter 2025 Results Key Financial Results Revenue: RM1.21b (up 1.5% from 2Q 2024). Net income: RM158.6m (up 2.2% from 2Q 2024). Profit margin: 13% (in line with 2Q 2024). EPS: RM0.017 (up from RM0.016 in 2Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Mr D.I.Y. Group (M) Berhad Revenues and Earnings Miss Expectations Revenue missed analyst estimates by 4.9%. Earnings per share (EPS) also missed analyst estimates by 2.6%. Looking ahead, revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Specialty Retail industry in Malaysia. Performance of the Malaysian Specialty Retail industry. The company's shares are down 2.5% from a week ago. Risk Analysis You should always think about risks. Case in point, we've spotted 1 warning sign for Mr D.I.Y. Group (M) Berhad you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
